Vol.

No.

November 12, 2021Nov 12, 2021

DOWNLOAD THE PDF

Cover Story

Project Equity: FDA considers options to increase diverse enrollment in clinical trials

By Matthew Bin Han Ong

FDA watchers and clinical trialists in oncology may want to pay close attention to the agency’s latest plans to increase representation of traditionally marginalized populations in drug development.

Conversation with The Cancer Letter Free Health Equity

FDA’s Lola Fashoyin-Aje: Stop getting stuck on the “risks” of diversity in drug development, it’s time to fix disparities in access

By Matthew Bin Han Ong

Conversation with The Cancer Letter Free Health Equity

NCTN group chairs, experts: Diverse representation of minorities in clinical trials and drug development saves lives

By Matthew Bin Han Ong

Capitol Hill

ARPA-H, the key element of Biden cancer agenda, faces uncertain future

By Alice Tracey

Free Obituary

Walter Lawrence, cancer surgeon and civil rights hero, dies at 96

By Robert A. Winn and Gordon D. Ginder

Free In the Archives

The National Cancer Act pioneers: The Roswell Park hearings and VCU Massey’s Walter Lawrence

Clinical Trials & Tribulations

Approval of an immunotherapy for adjuvant NSCLC indication gives us new reasons for finding early-stage disease

By Fred R. Hirsch

In Brief

Robert Califf nominated by President Biden as FDA commissioner

Ralph DeBerardinis, Sun Hur, Charles Swanton named winners of MSKCC’s 2021 Paul Marks Prize for Cancer Research

Fox Chase fundraising event raises over $1.5M

SEngine Precision Medicine, Dana-Farber partner to bring PARIS test to patients with CNS cancers

Rutgers Cancer Institute and RWJBarnabas Health establish state’s first home infusion program

Tiffany Haddish and Marlon Wayans featured in SU2C PSA for pancreatic cancer clinical trials

Clinical Roundup

ACS analysis quantifies progress made since the National Cancer Act

MD Anderson researchers find combination immunotherapy improves survival in asymptomatic melanoma brain metastases

Opdivo plus chemo becomes first immunotherapy-based treatment to improve EFS and pCR in NSCLC

Children’s Oncology Group finds drug combination helps children with acute promyelocytic leukemia avoid conventional chemotherapy

Hopkins study shows immunotherapy + chemo leads to improved survival in mesothelioma

USC study offers insights on leukemia progression and chemotherapy resistance

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 50 | Issue 41 - November 01, 2024

Project Equity: FDA considers options to increase diverse enrollment in clinical trials

FDA’s Lola Fashoyin-Aje: Stop getting stuck on the “risks” of diversity in drug development, it’s time to fix disparities in access

NCTN group chairs, experts: Diverse representation of minorities in clinical trials and drug development saves lives

ARPA-H, the key element of Biden cancer agenda, faces uncertain future

Walter Lawrence, cancer surgeon and civil rights hero, dies at 96

The National Cancer Act pioneers: The Roswell Park hearings and VCU Massey’s Walter Lawrence

Approval of an immunotherapy for adjuvant NSCLC indication gives us new reasons for finding early-stage disease

In Brief

Robert Califf nominated by President Biden as FDA commissioner

Ralph DeBerardinis, Sun Hur, Charles Swanton named winners of MSKCC’s 2021 Paul Marks Prize for Cancer Research

Fox Chase fundraising event raises over $1.5M

SEngine Precision Medicine, Dana-Farber partner to bring PARIS test to patients with CNS cancers

Rutgers Cancer Institute and RWJBarnabas Health establish state’s first home infusion program

Tiffany Haddish and Marlon Wayans featured in SU2C PSA for pancreatic cancer clinical trials

Clinical Roundup

ACS analysis quantifies progress made since the National Cancer Act

MD Anderson researchers find combination immunotherapy improves survival in asymptomatic melanoma brain metastases

Opdivo plus chemo becomes first immunotherapy-based treatment to improve EFS and pCR in NSCLC

Children’s Oncology Group finds drug combination helps children with acute promyelocytic leukemia avoid conventional chemotherapy

Hopkins study shows immunotherapy + chemo leads to improved survival in mesothelioma

USC study offers insights on leukemia progression and chemotherapy resistance

Recent Issues

Renew today!

Subscriber content

Login